The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Abstract
CD8+ cytotoxic T lymphocytes (CTLs) are preferred immune cells for targeting cancer. During cancer progression, CTLs encounter dysfunction and exhaustion due to immunerelated tolerance and immunosuppression within the tumor microenvironment (TME), with all favor adaptive immune‐resistance. Cancer‐associated fibroblasts (CAFs), macrophage type 2 (M2) cells, and regulatory T cells (Tregs) could make immunologic barriers against CD8 + T cell‐mediated antitumor immune responses. Thus, CD8 + T cells are needed to be primed and activated toward effector CTLs in a process called tumor immunity cycle for making durable and efficient antitumor immune responses. The CD8 + T cell priming is directed essentially as a corroboration work between cells of innate immunity including dendritic cells (DCs) and natural killer (NK) cells with CD4 + T cells in adoptive immunity. Upon activation, effector CTLs infiltrate to the core or invading site of the tumor (so‐called infiltrated–inflamed [I–I] TME) and take essential roles for killing cancer cells. Exogenous reactivation and/or priming of CD8 + T cells can be possible using rational immunotherapy strategies. The increase of the ratio for costimulatory to coinhibitory mediators using immune checkpoint blockade (ICB) approach. Programmed death‐1 receptor (PD‐1)–ligand (PD‐L1) and CTL‐associated antigen 4 (CTLA‐4) are checkpoint receptors that can be targeted for relieving exhaustion of CD8 + T cells and renewing their priming, respectively, and thereby eliminating antigen‐expressing cancer cells. Due to a diverse relation between CTLs with Tregs, the Treg activity could be dampened for increasing the number and rescuing the functional potential of CTLs to induce immunosensitivity of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Bourboulia, D., & Stetler-Stevenson, W. G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.05.002 · Cited by 710
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Chen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Induction and transcriptional regulation of the co-inhibitory gene module in T cells
Chihara, N., Madi, A., Kondo, T., Zhang, H., Acharya, N., Singer, M., Nyman, J., Marjanovic, N. D., Kowalczyk, M. S., Wang, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0206-z · Cited by 438
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Bertrand, F., Montfort, A., Marcheteau, E., Imbert, C., Gilhodes, J., Filleron, T., Rochaix, P., Andrieu-Abadie, N., Levade, T., Meyer, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02358-7 · Cited by 384 · cited 5×
“Recently, it has been identified a role for TNF in anti‐PD‐1 inducible effect on Tim‐3 expression in tumor‐infiltrating CD8+ T cells (Bertrand et al., 2017).”
BackgroundInfluentialCDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Kato, T., Noma, K., Ohara, T., Kashima, H., Katsura, Y., Sato, H., Komoto, S., Katsube, R., Ninomiya, T., Tazawa, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0205 · Cited by 367
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
Oweida, A., Hararah, M. K., Phan, A., Binder, D., Bhatia, S., Lennon, S., Bukkapatnam, S., Van Court, B., Uyanga, N., Darragh, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 274
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 249
Zhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248
Kansy, B. A., Concha-Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y., Moskovitz, J., Moy, J., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 246
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Xiang, W., Shi, R., Kang, X., Zhang, X., Chen, P., Zhang, L., Hou, A., Wang, R., Zhao, Y., Zhao, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04999-8 · Cited by 243
Ou, W., Thapa, R. K., Jiang, L., Soe, Z. C., Gautam, M., Chang, J.-H., Jeong, J.-H., Ku, S. K., Choi, H.-G., Yong, C. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.018 · Cited by 200
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response
Ubil, E., Caskey, L., Holtzhausen, A., Hunter, D., Story, C., & Earp, H. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97354 · Cited by 195
Bullock, T. N. J., & Yagita, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.710 · Cited by 182
van de Ven, K., & Borst, J. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 177
Gehring, A. J., Ho, Z. Z., Tan, A. T., Aung, M. O., Lee, K. H., Tan, K. C., Lim, S. G., & Bertoletti, A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.045 · Cited by 169
Siriwon, N., Kim, Y. J., Siegler, E., Chen, X., Rohrs, J. A., Liu, Y., & Wang, P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0502 · Cited by 169
Tommelein, J., De Vlieghere, E., Verset, L., Melsens, E., Leenders, J., Descamps, B., Debucquoy, A., Vanhove, C., Pauwels, P., Gespach, C. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0524 · Cited by 167
Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S., Carmon, K., Liu, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0152 · Cited by 165
Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation
Ahirwar, D. K., Nasser, M. W., Ouseph, M. M., Elbaz, M., Cuitiño, M. C., Kladney, R. D., Varikuti, S., Kaul, K., Satoskar, A. R., Ramaswamy, B., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0263-7 · Cited by 162
Tan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E. L., Hu, H., Chen, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2807 · Cited by 157
miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0600-x · Cited by 151
Mougiakakos, D., Johansson, C. C., Trocmé, E., All‐Ericsson, C., Economou, M. A., Larsson, O., Seregard, S., & Kiessling, R. W. (2010) · Cancer · doi:10.1002/cncr.24999 · Cited by 146
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Nejad, E. B., van der Sluis, T. C., van Duikeren, S., Yagita∥, H., Janssen, G. M. C., van Veelen, P. A., Melief, C. J. M., van der Burg, S. H., & Arens, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0881 · Cited by 144
Intermittent hypoxia induces a metastatic phenotype in breast cancer
Chen, A., Sceneay, J., Gödde, N., Kinwel, T., Ham, S., Thompson, E. W., Humbert, P. O., & Möller, A. (2018) · Oncogene · doi:10.1038/s41388-018-0259-3 · Cited by 133
CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
Ahrends, T., Bąbała, N., Xiao, Y., Yagita∥, H., van Eenennaam, H., & Borst, J. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3130 · Cited by 131
Kim, D.-H., Park, H., Lim, S., Koo, J., Lee, H., Choi, J. O., Oh, J. H., Ha, S.-J., Kang, M., Lee, C. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02731-6 · Cited by 129
Liu, Z., McMichael, E. L., Shayan, G., Li, J., Chen, K. C., Srivastava, R. M., Kane, L., Lu, B., & Ferris, R. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1350 · Cited by 125
Gangaplara, A., Martens, C., Dahlstrom, E. W., Metidji, A., Gokhale, A. S., Glass, D. D., Lopez-Ocasio, M. D., Baur, R., Kanakabandi, K., Porcella, S. F., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006985 · Cited by 119
IL-6 influences the polarization of macrophages and the formation and growth of colorectal tumor
Chen, L., Wang, S., Wang, Y., Zhang, W., Ma, K., Hu, C., Zhu, H., Liang, S., Liu, M., & Xu, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24734 · Cited by 118
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 115
Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114
The Potential Biomarkers and Immunological Effects of Tumor-Derived Exosomes in Lung Cancer
Alipoor, S. D., Mortaz, E., Varahram, M., Movassaghi, M., Kraneveld, A. D., Garssen, J., & Adcock, I. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00819 · Cited by 103
Zhang, Y., Wu, L., Li, Z., Zhang, W., Luo, F., Chu, Y., & Chen, G. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00305 · Cited by 99
Koehler, H., Kofler, D. M., Hombach, A. A., & Abken, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2098 · Cited by 95
Emerging Insights into Wnt/β-catenin Signaling in Head and Neck Cancer
Abalkhail, K. A., & Kukuruzinska, M. A. (2018) · Journal of Dental Research · doi:10.1177/0022034518771923 · Cited by 94
Wang, J., Sun, X., Ma, Q., Fu, G., Cong, L., Zhang, H., Fan, D., Feng, J., Lu, S., Liu, J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13655 · Cited by 92
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 92
Deng, W., Lira, V., Hudson, T. E., Lemmens, E. E., Hanson, W. G., Flores, R., Barajas, G., Katibah, G. E., Desbien, A. L., Lauer, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801910115 · Cited by 92
Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance
Hibino, S., Chikuma, S., Kondo, T., Ito, M., Nakatsukasa, H., Omata‐Mise, S., & Yoshimura, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3102 · Cited by 90
Borrelli, C., Ricci, B., Vulpis, E., Fionda, C., Ricciardi, M. R., Petrucci, M. T., Masuelli, L., Peri, A., Cippitelli, M., Zingoni, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0604 · Cited by 87
PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Adjuvant chemotherapy with melatonin for targeting human cancers: A review
Najafi, M., Salehi, E., Farhood, B., Nashtaei, M. S., Goradel, N. H., Khanlarkhani, N., Namjoo, Z., & Mortezaee, K. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27259 · Cited by 83
Self-citationAnti‐angiogenic effects of CD73‐specific siRNA‐loaded nanoparticles in breast cancer‐bearing mice
Ghalamfarsa, G., Rastegari, A., Atyabi, F., Hassannia, H., Hojjat‐Farsangi, M., Ghanbari, A., Anvari, E., Mohammadi, J., Azizi, G., Masjedi, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26743 · Cited by 82
Yang, J., Liu, R., Deng, Y., Qian, J., Lu, Z., Wang, Y., Zhang, D., Luo, F., & Chu, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30912 · Cited by 79
Proton irradiation orchestrates macrophage reprogramming through NFκB signaling
Genard, G., Wéra, A.-C., Huart, C., Calvé, B. L., Penninckx, S., Fattaccioli, A., Tabarrant, T., Demazy, C., Ninane, N., Heuskin, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0757-9 · Cited by 79
Hu, J., Sun, C., Bernatchez, C., Xia, X., Hwu, P., Dotti, G., & Li, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1365 · Cited by 76
Andersen, R. S., Borch, T. H., Draghi, A., Gokuldass, A., Rana, M. A. H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J. W., Westergaard, M. C. W., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy139 · Cited by 76
Chimote, A. A., Balajthy, A., Arnold, M. J., Newton, H. S., Hajdú, P., Qualtieri, J. N., Wise-Draper, T. M., & Conforti, L. (2018) · Science Signaling · doi:10.1126/scisignal.aaq1616 · Cited by 75
A Subset of Cancer-Associated Fibroblasts Determines Therapy Resistance
Huelsken, J., & Hanahan, D. (2018) · Cell · doi:10.1016/j.cell.2018.01.028 · Cited by 72
Human hepatocellular carcinoma: Protection by melatonin
Mortezaee, K. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26586 · Cited by 72
Self-citationChan, J. S. K., Sng, M. K., Teo, Z. Q., Chong, H. C., Twang, J. S., & Tan, N. S. (2017) · Oncogene · doi:10.1038/onc.2017.319 · Cited by 70
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Martin, A. M., Nirschl, C. J., Polanczyk, M. J., Bell, W. R., Nirschl, T. R., Harris‐Bookman, S., Phallen, J. A., Hicks, J. L., Martínez, D., Ogurtsova, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24951 · Cited by 66
Gottschalk, C., Mettke, E., & Kurts, C. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00379 · Cited by 65
Cancer-associated fibroblasts induce cancer cell apoptosis that regulates invasion mode of tumours
Itoh, G., Chida, S., Yanagihara, K., Yashiro, M., Aiba, N., & Tanaka, M. (2017) · Oncogene · doi:10.1038/onc.2017.49 · Cited by 57
Fu, R., Zhang, Y., Li, H., Lv, W., Zhao, L., Guo, Q., Lu, T., Weiss, S. J., Li, Z., & Wu, Z. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14351 · Cited by 54
Liu, Y., Geng, Y., Yang, H., Yang, H. K., Zhou, Y., Zhang, H., Tian, X., & Fang, W. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.043 · Cited by 52
Donzelli, S., Milano, E., Pruszko, M., Sacconi, A., Masciarelli, S., Iosue, I., Melucci, E., Gallo, E., Terrenato, I., Mottolese, M., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0990-2 · Cited by 52
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
Attili, I., Karachaliou, N., Bonanno, L., Berenguer, J., Bracht, J. W. P., Codony‐Servat, J., Codony, C., Ito, M., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763744 · Cited by 45
Liu, D., Li, G., Avella, D. M., Kimchi, E. T., Kaifi, J. T., Rubinstein, M. P., Camp, E. R., Rockey, D. C., Schell, T. D., & Staveley-O’Carroll, K. F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1372079 · Cited by 34
Yang, A., Kendle, R. F., Ginsberg, B. A., Roman, R., Heine, A. I., Pogoriler, E., Yuan, J., & Wolchok, J. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2555 · Cited by 28
Mutation-Specific T Cells for Immunotherapy of Gliomas
Melief, C. J. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmcibr1501818 · Cited by 25
Targeted Therapy for Cancer-Associated Fibroblasts: Are We There Yet?
Barnett, R. M., & Vilar, E. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx131 · Cited by 23
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Metadata
- Authors
- Farhood, B., Najafi, M., & Mortezaee, K.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-11-22
- Volume
- 234
- Issue
- 6
- Pages
- 8509-8521
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2905098668
- Cited by
- 1,658
- References
- 99
- FWCI
- 30.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.